The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer
- PMID: 34865865
- DOI: 10.1016/j.surg.2021.10.043
The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer
Abstract
Background: KRAS mutations, microsatellite instability, and tumor location have been found to be significant prognostic factors in colorectal cancer. The interaction between these variables and its effect on overall survival in nonmetastatic colon cancer has not been well elucidated.
Methods: The National Cancer Database (2010-2016) was queried for patients with stage I-III colon cancer and known microsatellite instability and KRAS status undergoing curative resection.
Results: A total of 5,292 patients were identified: 60.4% had right-sided cancers, 36.4% had KRAS mutations, and 15.6% had microsatellite instability. Right-sided tumors were more likely to have microsatellite instability and KRAS mutations compared to left-sided tumors. On univariable analysis, KRAS mutations and microsatellite instability status were not associated with differences in survival, whereas right-sided cancers had worse overall survival compared to left-sided cancers (hazard ratio 1.32, 95% confidence interval: 1.18-1.47). On multivariable analysis, right-sided location, KRAS mutations, and microsatellite instability were not independent prognostic factors. However, a significant interaction between laterality and KRAS status was observed. In patients with mutated KRAS cancers, left-sided tumors were at increased risk of death compared to right-sided tumors (hazard ratio: 1.30, 95% confidence interval: 1.03-1.63), whereas in patients with wild-type KRAS cancers, left-sided tumors were at decreased risk of death (hazard ratio: 0.81, 95% confidence interval: 0.67-0.97).
Conclusion: In patients with stage I-III colon cancer, laterality, KRAS mutation, and microsatellite instability status were not independently prognostic after curative resection. However, the effect of laterality was opposite based on KRAS status, with left-sided (compared to right-sided) tumors associated with worse overall survival in mutated KRAS patients and better overall survival in wild-type KRAS individuals. Laterality itself may not be an independent prognostic factor but a reflection of differing genetic profiles within the colon.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.Int J Cancer. 2016 Mar 1;138(5):1139-45. doi: 10.1002/ijc.29855. Epub 2015 Oct 23. Int J Cancer. 2016. PMID: 26376292
-
Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.Ann Surg Oncol. 2016 Oct;23(11):3736-3743. doi: 10.1245/s10434-016-5361-6. Epub 2016 Jun 28. Ann Surg Oncol. 2016. PMID: 27352204
-
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12. JAMA Oncol. 2018. PMID: 29167892 Free PMC article.
-
Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.J Natl Compr Canc Netw. 2017 Mar;15(3):411-419. doi: 10.6004/jnccn.2017.0038. J Natl Compr Canc Netw. 2017. PMID: 28275039 Review.
-
The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysis.J Gastrointest Surg. 2016 Mar;20(3):648-55. doi: 10.1007/s11605-015-3026-6. Epub 2015 Nov 16. J Gastrointest Surg. 2016. PMID: 26573851 Review.
Cited by
-
KRAS mutations and their associations with clinicopathological features and survival in Vietnamese non‑polyp colon cancer patients.Mol Clin Oncol. 2023 Jun 30;19(2):63. doi: 10.3892/mco.2023.2659. eCollection 2023 Aug. Mol Clin Oncol. 2023. PMID: 37456800 Free PMC article.
-
Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.Int J Mol Sci. 2023 May 22;24(10):9073. doi: 10.3390/ijms24109073. Int J Mol Sci. 2023. PMID: 37240418 Free PMC article.
-
Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors.Life (Basel). 2023 Jan 31;13(2):395. doi: 10.3390/life13020395. Life (Basel). 2023. PMID: 36836752 Free PMC article. Review.
-
KRAS: A Druggable Target in Colon Cancer Patients.Int J Mol Sci. 2022 Apr 8;23(8):4120. doi: 10.3390/ijms23084120. Int J Mol Sci. 2022. PMID: 35456940 Free PMC article. Review.
-
TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma.Front Genet. 2022 Mar 25;13:844800. doi: 10.3389/fgene.2022.844800. eCollection 2022. Front Genet. 2022. PMID: 35401671 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
